Alyson Haslam
Articles
-
1 month ago |
medrxiv.org | William Ward |Alyson Haslam |Vinay Prasad
Disclosure: V.P. receives research funding from Arnold Ventures through a grant made to UCSF, and royalties for books and writing from Johns Hopkins Press, MedPage, and the Free Press.
-
2 months ago |
onlinelibrary.wiley.com | Alyson Haslam |Timothée Olivier |Vinay Prasad
CONFLICT OF INTEREST STATEMENT V. P. receives research funding from Arnold Ventures through a grant made to UCSF and royalties for books and writing from Johns Hopkins Press, MedPage, and the Free Press.
-
Jan 23, 2025 |
medrxiv.org | Alyson Haslam |Sarah Miller |Vinay Prasad
V.P. receives research funding from Arnold Ventures through a grant made to UCSF, and royalties for books and writing from Johns Hopkins Press, MedPage, and the Free Press.
-
Jun 20, 2024 |
jamanetwork.com | Timothée Olivier |Alyson Haslam |Vinay Prasad
Key PointsQuestion How often is postrecurrence treatment reported in adjuvant and neoadjuvant oncology randomized clinical trials, and what is the access to optimal postrecurrence treatment? Findings In this systematic review of 14 US Food and Drug Administration registration trials of systemic therapy in the neoadjuvant or adjuvant setting from 2018 to 2023, postrecurrence treatment was not reported in 43% of trials. Overall, 14% of trials had data assessed as appropriate.
-
Mar 16, 2024 |
onlinelibrary.wiley.com | David Benjamin |Alyson Haslam |Vinay Prasad
1 INTRODUCTION Cancer remains the leading cause of morbidity in many countries with an estimated 19.3 million new cancer cases and nearly 10.0 million deaths globally in 2020 alone.1 Despite the development and approval of therapeutics such as immune checkpoint inhibitors and drugs targeting specific oncogenic driver mutations, many individuals with cancer remain ineligible for these therapies and many cancers remain incurable.2-4 As such, cancer continues to inflict devastating financial and...
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →